DDL Biopharma AS was established in April 2010 as a wholly owned subsidiary of Drug Discovery Laboratory AS.
The company is headed by Aase Jorun Klaveness, M. Sc. Pharm.
The most promising project within treatment of skin conditions is taken into preclinical and clinical development in DDL Biopharma AS. The new chemical compound, resulting from research activities in Drug Discovery Laboratory AS, is a potent version of another anti-acne compound in current clinical use. Product patents have been issued in Europe, US, Canada, Japan, China, Russia and Australia.
An early clinical pilot study has been performed in 6 patients at the dermatology department of the University hospital in Oslo. This gave very promising results with respect to efficacy in the treatment of a moderate degree of acne.
A plan for the documentation program has been established and discussed with the Medical Products Agency (Sweden).
Innovation Norway has given some financial support to the project. For the remaining project development we would welcome a partner coming from "Big Pharma".